ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Integrating deep learning and radiomics for precise identification of luminal A/B breast cancer subtypes on dynamic contrast-enhanced MRI.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate differentiation between luminal A and B subtypes of breast cancer is critical for selecting therapeutic strategies. However, current approaches rely predominantly on invasive biopsy and immunohistochemical (IHC) analysis. Therefore, the development of non-invasive imaging-based methods capable of reliably classifying tumor subtypes remains an urgent task.
methodsTo develop and validate a hybrid classification model combining radiomic and deep learning features extracted from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to differentiate between luminal A and B subtypes of invasive breast cancer. The study included 312 women from China, Russia and Bulgaria with confirmed luminal subtypes of breast cancer. All patients underwent standardized pre-treatment DCE-MRI, and subtypes were determined using IHC. Tumors were semi-automatically segmented, and radiomic features were extracted using PyRadiomics. Additionally, deep features were extracted from DCE-MRI using a 3D ResNet-50 convolutional neural network. Three models were constructed: a radiomics-based model, a deep learning-based model, and a hybrid model that integrated both approaches using a stacking ensemble method. Model performance was evaluated using AUC, sensitivity, specificity, and other metrics on a test dataset and an independent external validation cohort (n = 148). SHAP and Grad-CAM techniques were applied for model interpretability.
resultsThe hybrid model significantly outperformed the individual approaches, achieving an AUC of 0.921, sensitivity of 88.6%, and specificity of 89.7% on the test dataset. Performance remained robust in the external validation cohort (AUC = 0.903). Statistical tests (DeLong and bootstrapping) confirmed the significance of these differences. The most important contributors were radiomic features related to shape and texture (e.g., entropy, sphericity) and high-level deep features. Visualizations highlighted clinically relevant model attention areas.
conclusionThe proposed hybrid approach represents a clinically applicable, non-invasive method for classifying breast cancer subtypes, potentially complementing or partially replacing biopsy in selected cases. It enhances diagnostic accuracy while maintaining interpretability. Future work will focus on prospective validation and integration with genomic and clinical data within the framework of precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.